Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC) [...].
Authors
- Ryota Saito (ORCID: https://orcid.org/0000-0003-4289-7891)
- Shin Saito (ORCID: https://orcid.org/0000-0002-2931-4260)
- Hisashi Tanaka (ORCID: https://orcid.org/0000-0003-2009-0210)
- Taku Nakagawa (ORCID: https://orcid.org/0000-0003-1281-2412)
- Yosuke Kawashima (ORCID: https://orcid.org/0000-0002-9824-6572)
- Minehiko Inomata (ORCID: https://orcid.org/0000-0002-6846-187X)
- Yoko Tsukita (ORCID: https://orcid.org/0000-0003-3958-8641)
- Hiromi Nagashima (ORCID: https://orcid.org/0000-0003-1271-1152)
- Shunichi Sugawara (ORCID: https://orcid.org/0000-0002-3427-4558)
- Naruo Yoshimura (ORCID: https://orcid.org/0000-0003-1712-9540)
Institutions
- Iwate Medical University (JP)
- Tohoku University (JP)
- Tohoku Medical and Pharmaceutical University Hospital (JP)
- Toyama University Hospital (JP)
- Hirosaki University Hospital (JP)
- Yamanashi Prefectural Central Hospital (JP)
- Sendai Kousei Hospital (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3390/cancers17091551
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05